Initial report of a phase II study with R-FND followed by ibritumomab tiuxetan radioimmunotherapy and rituximab maintenance in patients with untreated high-risk follicular lymphoma
暂无分享,去创建一个
Maria A. Rodriguez | P. Mclaughlin | S. Neelapu | M. Fanale | F. Hagemeister | B. Pro | F. Samaniego | L. Nastoupil | N. Fowler | L. Feng | E. Taylor | M. Rodriguez | Lei Feng